AlphaStreet Newsdesk powered by AlphaStreet Intelligence
Molina Healthcare surged 5.7% on Tuesday to $189.44 after five major Wall Street firms raised their price targets on the managed care provider, with the average new target climbing 18.3%. The coordinated bullish action sent the stock sharply higher as analysts across the Street reappraised the company’s valuation.
The upgrade wave was led by Truist Securities and UBS, both lifting their targets to $180. Truist maintained its Hold rating while boosting its price target from $145, while UBS kept a Neutral stance as it raised from $151. Wells Fargo moved its Equal-Weight target from $141 to $159, while Morgan Stanley adjusted from $128 to $146, also maintaining Equal-Weight. Even Barclays, which holds an Underweight rating, raised its target from $133 to $161. The average new price target across the five firms now sits at $165, implying further upside from current levels.
Trading volume reflected heightened investor interest, with 728,534 shares changing hands as the stock vaulted higher. The price action adds momentum to Molina’s $9.9 billion market capitalization, though the stock remains below most of the newly established analyst targets. The cluster of simultaneous upgrades suggests analysts are responding to improved fundamentals or sector dynamics in the healthcare plans space, though none of the firms shifted to outright bullish ratings.
The muted ratings despite higher targets highlight continued caution on Wall Street. With all five firms maintaining neutral or negative stances—ranging from Underweight to Equal-Weight and Hold—analysts appear to be acknowledging improved prospects while stopping short of full endorsement. The gap between today’s closing price of $189.44 and the $165 average target suggests the market may be pricing in optimism that analysts have yet to fully embrace.
This content is for informational purposes only and should not be considered investment advice. AlphaStreet Intelligence analyzes financial data using AI to deliver fast and accurate market information. Human editors verify content.
